Unicycive Therapeutics, Inc. - Common Stock (UNCY)
0.5800
-0.3200 (-35.56%)
NASDAQ · Last Trade: Jun 10th, 1:09 PM EDT
Detailed Quote
Previous Close | 0.9000 |
---|---|
Open | 0.4980 |
Bid | 0.5799 |
Ask | 0.5800 |
Day's Range | 0.4700 - 0.7300 |
52 Week Range | 0.2020 - 1.100 |
Volume | 39,933,833 |
Market Cap | - |
PE Ratio (TTM) | - |
EPS (TTM) | - |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 3,289,228 |
Chart
About Unicycive Therapeutics, Inc. - Common Stock (UNCY)
Unicycive Therapeutics Inc is a biotechnology company focused on developing innovative therapies to address unmet medical needs, particularly in the areas of kidney diseases. The company is primarily engaged in creating novel drug candidates that enhance the management of renal conditions, aiming to improve patient outcomes through targeted treatments. By leveraging its expertise in drug development and its commitment to scientific research, Unicycive Therapeutics seeks to bring forth new solutions that can significantly impact the lives of individuals suffering from various kidney-related disorders. Read More
News & Press Releases
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis.
Via Chartmill · June 10, 2025
Unicycive announced update on its NDA for oxylanthanum carbonate to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.
Via Benzinga · June 10, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · June 10, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · June 10, 2025
Via Benzinga · June 10, 2025

Via Benzinga · June 2, 2025

Discover the top movers in Monday's after-hours session and stay informed about the post-market dynamics.
Via Chartmill · June 2, 2025
Shalabh Gupta, CEO of Unicycive Therapeutics Inc. (NASDAQ: UNCY), to Present at NobleCon20
Unicycive Therapeutics (NASDAQ: UNCY) is at the forefront of developing cutting-edge therapies for kidney diseases. The company will be presenting alongside world-class headliners such as Zack Kass, former Head of Go-To-Market at OpenAI where ChatGPT was created, and “Shark Tank” stars Kevin O’Leary, Robert Herjavec, and Daymond John.
Via Investor Brand Network · November 19, 2024

Via Benzinga · October 11, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · September 20, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · September 16, 2024

UNCY stock results show that Unicycive Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 14, 2024

Pre-market stock movers are a hot topic on Friday as we check out all of the stories affecting shares on the last day of trading this week!
Via InvestorPlace · July 19, 2024

Via Benzinga · July 8, 2024

Via Benzinga · June 11, 2024

Via Benzinga · May 28, 2024

Via Benzinga · May 22, 2024

UNCY stock results show that Unicycive Therapeutics missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 13, 2024

UNCY stock results show that Unicycive Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
Via InvestorPlace · March 28, 2024

Via Benzinga · March 14, 2024

Shares of Limbach Holdings, Inc. (NASDAQ: LMB) fell sharply during Thursday’s session after the company reported fourth-quarter financial results and issued FY24 revenue guidance below estimates.
Via Benzinga · March 14, 2024

Via Benzinga · March 7, 2024

Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
Via Benzinga · January 22, 2024

Shares of 3M Company (NYSE: MMM) fell sharply during Tuesday’s session after the company reported better-than-expected fourth-quarter EPS, but issued FY24 EPS guidance below estimates.
Via Benzinga · January 23, 2024

We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday!
Via InvestorPlace · January 22, 2024